Biovest Management Team

Francis E. O'Donnell, Jr. MD

Chairman

Dr. O'Donnell has served as Chairman of the Board of Accentia Biopharmaceuticals, Inc. since November, 1998 and as CEO since May 2003. Dr O'Donnell is a 1975, summa cum laude graduate of the Johns Hopkins School of Medicine. He received his specialty training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. He is the former Professor and Chairman, Dept of Ophthalmology, St Louis University School of Medicine. He is the Founder and Managing Partner of The Hopkins Capital Group (HCG), LLC, a leading biotech investment/business development company. The HCG specializes in early-stage investments in disruptive innovations in healthcare. Dr O'Donnell has published over 30 peer-reviewed scientific articles and he has been awarded 34 US Patents. He is the recipient of the 2000 Jules Stein Award from Retinitis Pigmentosa International.

Samuel S. Duffey, Esq.

President and General Counsel

Named as President in December 2008, Mr. Duffey, has also served as our General Counsel since April 2003. Prior to that, Mr. Duffey practiced business law with Duffey and Dolan P.A. beginning in 1992. From February 2000, to September 2003, Mr. Duffey served as the non-executive chairman and as a member of the board of directors of Invisia, Inc., a small publicly held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive chairman and as a member of the board of directors of FlashPoint International, Inc., a publicly held automotive parts company which is currently named Navitrak International Corporation. Mr. Duffey received his B.A. and J.D. degrees from Drake University.

Mark Hirschel, Ph.D.

Chief Scientific Officer

Mark Hirschel, Ph.D. has headed-up our science and technology departments since September 2001. From August 1999 until September 2001, he was our Senior Vice President. Dr. Hirschel has served as the Principal Investigator of the National Cell Culture Center and is a recognized leader in cell culture production. Dr.Hirschel has authored numerous scientific publications and has received several grants and served on several NIH committees. Dr. Hirschel holds a BA in biology from Southwest State University (MN), an MS in Animal Physiology, and a Ph.D. in Reproductive Physiology from the University of Minnesota.

Alan Pearce
Chief Financial Officer

Mr. Pearce recently retired as Senior Vice President, Financial Services of McKesson Corporation after 27 years with the firm. McKesson Corporation, a publicly traded Fortune 20 company (NYSE: MCK), is the leading provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. Mr. Pearce held his last position since April 1999. Prior to this date he was treasurer of McKesson Corporation. Mr. Pearce currently serves on the board of directors and a member of the audit committee of BioDelivery Sciences International, Inc., a publicly traded drug delivery technology company (NASDAQ: BDSI). Mr. Pearce also currently serves on the advisory boards of Georgia Tech-Emory University BioEngineering Foundation and Hopkins Capital Group, a venture capital firm specializing in the healthcare field, and has previously served as a director and a member of the finance committee of XL Insurance. He is a graduate of Georgia Institute of Technology, where he earned a BS in Industrial Management and University of Texas, where he earned his MBA in finance.

David D. Moser
Corporate Secretary

Board of Directors

Stephen Arikian, M.D.               
Francis E. O’Donnell, M.D.
Raphael Mannino, Ph.D.
Peter J. Pappas, Sr.
John Sitilides
Christopher Chapman, M.D.
Jeffery Scott, M.D.
Ronald E. Osman